Cargando…
Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer Health
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489192/ https://www.ncbi.nlm.nih.gov/pubmed/35797511 http://dx.doi.org/10.1200/PO.22.00040 |
| _version_ | 1784792823735779328 |
|---|---|
| author | Urbanska, Edyta M. Sørensen, Jens B. Melchior, Linea C. Costa, Junia C. Santoni-Rugiu, Eric |
| author_facet | Urbanska, Edyta M. Sørensen, Jens B. Melchior, Linea C. Costa, Junia C. Santoni-Rugiu, Eric |
| author_sort | Urbanska, Edyta M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9489192 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Wolters Kluwer Health |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94891922022-09-21 Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer Urbanska, Edyta M. Sørensen, Jens B. Melchior, Linea C. Costa, Junia C. Santoni-Rugiu, Eric JCO Precis Oncol Case Reports Wolters Kluwer Health 2022-07-07 /pmc/articles/PMC9489192/ /pubmed/35797511 http://dx.doi.org/10.1200/PO.22.00040 Text en © 2022 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution Non-Commercial No Derivatives 4.0 License http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
| spellingShingle | Case Reports Urbanska, Edyta M. Sørensen, Jens B. Melchior, Linea C. Costa, Junia C. Santoni-Rugiu, Eric Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer |
| title | Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer |
| title_full | Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer |
| title_fullStr | Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer |
| title_full_unstemmed | Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer |
| title_short | Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer |
| title_sort | durable response to combined osimertinib and pralsetinib treatment for osimertinib resistance due to novel intergenic ank3-ret fusion in egfr-mutated non–small-cell lung cancer |
| topic | Case Reports |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489192/ https://www.ncbi.nlm.nih.gov/pubmed/35797511 http://dx.doi.org/10.1200/PO.22.00040 |
| work_keys_str_mv | AT urbanskaedytam durableresponsetocombinedosimertinibandpralsetinibtreatmentforosimertinibresistanceduetonovelintergenicank3retfusioninegfrmutatednonsmallcelllungcancer AT sørensenjensb durableresponsetocombinedosimertinibandpralsetinibtreatmentforosimertinibresistanceduetonovelintergenicank3retfusioninegfrmutatednonsmallcelllungcancer AT melchiorlineac durableresponsetocombinedosimertinibandpralsetinibtreatmentforosimertinibresistanceduetonovelintergenicank3retfusioninegfrmutatednonsmallcelllungcancer AT costajuniac durableresponsetocombinedosimertinibandpralsetinibtreatmentforosimertinibresistanceduetonovelintergenicank3retfusioninegfrmutatednonsmallcelllungcancer AT santonirugiueric durableresponsetocombinedosimertinibandpralsetinibtreatmentforosimertinibresistanceduetonovelintergenicank3retfusioninegfrmutatednonsmallcelllungcancer |